Zami Aberman
2022
In 2022, Zami Aberman earned a total compensation of $1.2M as Chairman at Pluristem Therapeutics, a 88% decrease compared to previous year.
Compensation breakdown
Salary | $432,043 |
---|---|
Other | $751,472 |
Total | $1,183,515 |
Aberman received $751.5K in other compensation, accounting for 63% of the total pay in 2022.
Aberman also received $432K in salary.
Rankings
In 2022, Zami Aberman's compensation ranked 2,712th out of 5,760 executives tracked by ExecPay. In other words, Aberman earned more than 52.9% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 2,712 out of 5,760 | 53rd |
Division Manufacturing | 1,508 out of 3,136 | 52nd |
Major group Chemicals And Allied Products | 697 out of 1,422 | 51st |
Industry group Drugs | 649 out of 1,323 | 51st |
Industry Biological Products, Except Diagnostic Substances | 158 out of 291 | 46th |
Source: SEC filing on February 27, 2023.
Aberman's colleagues
We found two more compensation records of executives who worked with Zami Aberman at Pluristem Therapeutics in 2022.
News
Pluristem Therapeutics CEO Yaky Yanay's 2022 pay falls 86% to $1.3M
February 27, 2023
Pluristem Therapeutics Chairman Zami Aberman's 2020 pay falls 54% to $501K
April 8, 2021
Pluristem Therapeutics Chairman Zami Aberman's 2019 pay jumps 85% to $1.1M
May 20, 2020
Pluristem Therapeutics CEO Zami Aberman's 2018 pay falls 83% to $593K
April 25, 2019